TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target
Benzinga Newsdesk 10 months ago
NewsUpgradesPrice TargetAnalyst Ratings
TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and announces $8 price target.
TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and announces $8 price target.